Icaritin clinical trials
Also written SNG-162 and IC-162.
How each study uses icaritin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the icaritin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2017 | 2 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 6
Beijing Shenogen Biomedical Co., Ltd (4) · Chinese Academy of Medical Sciences (2) · Sir Run Run Shaw Hospital (2) · Henan Cancer Hospital (1) · Nanjing Tianyinshan Hospital (1)
Often tested with
Tested in the same studies.
Bevacizumab (2) · FOLFOX-4 Regimen (1) · Adebrelimab (1) · Apatinib (1) · SHR-1701 (1) · Iparomlimab/Tuvonralimab (1) · FOLFIRI-Ziv-aflibercept Regimen (1) · FOLFIRI Regimen (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test icaritin.
- Apr 2027Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal AdenocarcinomaPhase 2 · Sir Run Run Shaw Hospital
Studies
Open first, then newest update. How each study uses icaritin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNot applicableNanjing Tianyinshan HospitalNCT06893887Written as IcaritinHow we know
- Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal AdenocarcinomaRecruitingPhase 2Sir Run Run Shaw HospitalNCT06825546Written as IcaritinHow we know
- Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)RecruitingPhase 3Beijing Shenogen Biomedical Co., LtdNCT05594927Written as IcaritinHow we know
- Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B PatientsNot yet recruitingPhase 2Henan Cancer HospitalNCT06285149Written as IcaritinHow we know
- The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal CancerRecruitingPhase 4Sir Run Run Shaw HospitalNCT06269445Written as Icaritin Combined With Bevacizumab and FOLFIRIHow we know
- The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedPhase 3Beijing Shenogen Biomedical Co., LtdNCT03236649Written as IcaritinHow we know
- The Phase II Study of Icaritin in Patients With Advanced Hepatocellular CarcinomaCompletedPhase 2Beijing Shenogen Biomedical Co., LtdNCT01972672Written as IcaritinHow we know
- The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownPhase 3Beijing Shenogen Biomedical Co., LtdNCT03236636Written as IcaritinHow we know
- A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid TumorsCompletedPhase 1Chinese Academy of Medical SciencesNCT02496949Written as IcaritinHow we know
- Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer PatientsStatus unknownPhase 1Chinese Academy of Medical SciencesNCT01278810Written as IcaritinHow we know
Codes
What other systems call icaritin · ClinicalTrials.gg INT004757
- MeSH (NLM) C499403icaritinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) UFE666UELYICARITINConfirmed NLM, Wikidata
- Wikidata Q27291061icaritinConfirmed NLM, Wikidata
- DrugBank DB12672One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C499403 | icaritin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | UFE666UELY | ICARITIN | Confirmed NLM, Wikidata |
| Wikidata | Q27291061 | icaritin | Confirmed NLM, Wikidata |
| DrugBank | DB12672 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.